Liz Beatty is co-founder and chief strategy officer at Inato, a clinical trials platform which flips the traditional model and allows community sites to participate in the trials that are best aligned with their interests and that of their patients.
Cumulus Neuroscience, a global digital health company focused on advancing neuroscience clinical trials and patient care, presented interim data from their first-in-class CNS-102 feasibility study at the European Network to Cure ALS Annual Meeting (ENCALS)...
2San, a supplier of self-diagnostic tests, has partnered with Proov to distribute their proprietary at-home fertility tests in select Hy-Vee stores across eight states in the Midwest.
Ora, a clinical research organization (CRO) for ophthalmology pharmaceutical and device development, has partnered the North West London Clinical Trials Alliance, to improve the quality and access to clinical research in the region.
Jason Dong, co-CEO-founder of Mural Health, wants to make sure patients taking part in trials are not out of pocket. He joined OSP while at DIA Global to discuss how his business came about and why it is so important.
Updated guidelines for risk-based quality management (RBQM) are much more than just for monitoring purposes and can show quality by design concepts, save immeasurable time on manpower and shows there has been a complete mindset shift within the last 15...
OSP spoke to senior director of clinical trials, Erin Leckrone, and Kathleen Kane, senior manager of clinical operations at Be The Match Biotherapies, to discuss how creating a well-designed and reviewed protocol is critical to a study's overall...
With the FDA issuing guidance on more diversity within clinical trials, it is a subject many companies are being encouraged to focus on, each with their own approach.
Lucy Jung is the CEO and founder at Charco Neurotech, a medtech start-up which has developed the CEU1, a wearable device for Parkinson's, that uses vibrotactile stimulation to reduce symptoms of slowness and stiffness - resulting in improved movement....
New guidelines have been issued by the FDA called Diversity Plans to Improve Enrollment of Participants from Underrepresented Racial and Ethnic Populations in Clinical Trials. Curavit was ahead of the game with its plans, find out how.
RAIR Health, an applied data and AI company focused on the extraction of clinical insights from real world data, has signed a non-exclusive data license agreement with Royal Cornwall Hospitals NHS Trust (RCH) focussed on the field of ophthalmology.
Kicking off a series of DIA Global interviews in Boston, OSP had the pleasure of speaking to Cal Collins, co-founder and CEO of OpenClinica - a company that wants to empower data managers, clinical researchers, and study participants.
uMotif is starting to reap the rewards of its patient first technology – that really does what it says on the tin, says the company’s CEO, Steve Rosenberg.
The escalation of a drug targeting tumors, by releasing active chemotherapy into the disease tissue, has had ‘remarkable’ results and also shown a reduction in side-effects.
Coordinating with Migraine and Headache Awareness Month (MHAM), this June, Pfizer has announced it is partnering with multi-award winning, singer and actress, Lady Gaga, who was diagnosed with migraine when she was 14.
Multinational pharmaceutical company, Gedeon Richter UK Ltd, announced this week that it has acquired full marketing and distribution rights to a contraceptive range.
Mural Health is on a mission to make it as easy as possible for people to take part in clinical trials, the company will be heading to DIA Global in Boston where they hope to glean a meaningful understanding of the current landscape and hot topics.
The message mdgroup, an organization devoted to creating 'remarkable patient experiences through solutions for clinical trial recruitment, engagement, retention, and outcomes', is that its focus is on people not technology.
Slope, a site-first organization, ‘eliminating the chaos’ impacting clinical trials has joined CancerX as a founding member of The White House’s national Cancer Moonshot.
Sygnature Discovery has launched an in vivo inflammation model, that the company says is ‘exciting but only the beginning’ of understanding life-limiting neuroinflammatory conditions.
Artificial intelligence (AI) biotech company, Owkin, has invested $50million in a project that will use spatial omics, a set of cutting-edge technologies that offer unprecedented information on the structure of tumors.
Duchenne Muscular Dystrophy (DMD) is a genetic disorder that primarily affects males, caused by a mutation in the gene that encodes for a protein called dystrophin. This protein is crucial for the normal functioning of muscles, and its absence leads to...
A healthcare company on a mission to produce a multi-cancer early detection (MCED) test so patients have more chance of being cured, has produced 'exciting results' from a study.
Research has reinforced the efficacy of Lumakras (sotorasib), a small molecule inhibitor in advanced non-small cell lung cancer (NSCLC) and metastatic colorectal cancer (mCRC).
Jim Murphy is Greenphire's CEO and leads the company's strategy and he says he is committed to fostering a culture of growth, innovation, excellence and employee satisfaction. Under his leadership, the company has expanded exponentially - in...
'Compelling and landmark' results will ‘fundamentally change’ the journey of patients with stage 2 and 3 early breast cancer, specifically those in need of new, well-tolerated options to prevent their cancer from coming back.
H1, a US data healthcare data technology company has been selected by non-profit funder of Parkinson’s Disease (PD) research, The Michael J Fox Foundation (MJFF), for its Trial Landscape solution.
A partnership has been formed between Allucent, a biopharma services provider, has partnered with Thread, a decentralized clinical trial (DCT) and eCOA technology provider to launch Allucent Patient Direct Trials, a DCT focusing on small and mid-sized...
Vicore Pharma’s drug candidate, C21 formulation, currently in a phase 2a trial aimed at people with idiopathic pulmonary fibrosis (IPF), has been patented.
The UK has the tools to become a life-sciences superpower but those thinking about taking part remain put off by the lack of financial motivation, a clinical trials start-up says.
The UK Government has announced plans to allow patients in England to receive prescription medicines directly from pharmacies without the need for a GP appointment.
AARDEX Group has joined forces with other industry companies to partner with a new project from The Digital Medical Society (DiMe) called Extending the Verification, Analytical Validation, and Clinical Validation – or V3+ Framework.
Two contract research organizations working in the clinical trial and research fields have benefited from investment from Iberian private equity firm, Henko Partners.
As part of a new initiative, the generic manufacturer will boost access to treatments for anxiety and depression across seven new states across the US, potentially reaching more than 650,000 uninsured patients.
Cumulus Neuroscience has been given the clearance by the US Food and Drug Administration (FDA) and the company says this will accelerate treatments for neuropsychiatric and neurodegenerative disorders.
Results from a multinational trial of trifluridine/tipracil, known as Lonsurf, with or without bevacizumab in refractory metastatic colorectal cancer (mCRC) have resulted in statistically significantly and clinically meaningful improvements.
Scorpion Therapeutics, a clinical-stage oncology company, has announced that the first patient has been dosed in a phase 1/2 clinical trial of STX-478, its treatment for breast cancer and other solid tumors.
Galapagos NV has announced it has initiated a phase 3 study with small molecule drug filgotinib in patients with the chronic, highly inflammatory condition, active axial spondyloarthritis(AxSpA).
Neuraxapharm Group, a European-based pharmaceutical company that focuses on central nervous system (CNS) announced last week that it had signed a binding agreement to divest API developer and manufacturer company, Inke, to private equity manager Keensight...
Symptom improvements have been hailed as ‘very compelling’ after results from a phase 1 study into a combination of drugs to treat myelofibrosis prove positive.
A drug to treat a rare cancer that grows where the esophagus and stomach join has been accepted for review by the China National Medical Products Administration (NMPA).
